MedTrace Logo

The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology

NCT02129998 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 873

Last updated 2017-10-09

No results posted yet for this study

Summary

The aim of this study is to achieve a more profound understanding of the endocrine alteration in luteal progesterone level after gonadotrophin stimulated IVF/ICSI cycles and to explore the optimal progesterone level needed for securing implantation and development of early pregnancy.

The second part of the project will determine the value of Preimplantation Factor (PIF) measurement in embryo culture medium as a possible tool for improved embryo selection and the use of PIF as an early pregnancy serum marker for healthy implantation and embryo development.

IVF: In vitro fertilisation, ICSI: Intracytoplasmic sperm injection.

Conditions

Interventions

OTHER

IVF/ICSI treatment

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • BioIncept LLC

    collaborator INDUSTRY

  • Regionshospitalet Viborg, Skive

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-07-31
Completion
2017-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129998 on ClinicalTrials.gov